Filing Details

Accession Number:
0001415889-24-021731
Form Type:
4
Zero Holdings:
No
Publication Time:
2024-08-20 18:46:23
Reporting Period:
2024-08-16
Accepted Time:
2024-08-20 18:46:23
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1070494 Acadia Pharmaceuticals Inc ACAD Pharmaceutical Preparations (2834) 061376651
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1899977 C. Mark Schneyer C/O Acadia Pharmaceuticals Inc.
12830 El Camino Real, Suite 400
San Diego CA 92130
Evp, Chief Financial Officer No No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2024-08-16 5,275 $0.00 39,839 No 4 A Direct
Common Stock Acquisiton 2024-08-16 13,629 $0.00 53,468 No 4 A Direct
Common Stock Disposition 2024-08-19 9,733 $15.28 43,735 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 A Direct
No 4 A Direct
No 4 S Direct
Footnotes
  1. Represents acquisition of the Issuer's common stock upon vesting of the performance stock units granted to the Reporting Person on April 5, 2022 at incremental 25% of target. Together with the vesting on March 25, 2024, the performance stock units have vested at 75% of target.
  2. Represents acquisition of the Issuer's common stock upon vesting of the performance stock units granted to the Reporting Person on May 1, 2023 at 50% of target.
  3. The mandatory sales reported in this Form 4 were made to cover withholding taxes and tax related items imposed by the Issuer in connection with the vesting of performance stock units, and it is intended to comply with the requirements of Rule 10b5-1(c)(1)(i)(B) under the Exchange Act and be interpreted to meet the requirements of Rule 10b5-1(c).
  4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.28 to $15.32, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.